NCT07262398

Brief Summary

Background: In the context of day-case surgery, the optimal spinal anesthetic should give immediate and effective anesthesia for an appropriate period, followed by rapid regression of sensory and motor blocking, rapid bladder voiding, and little residual effects to allow for early ambulation and discharge. Although bupivacaine is safe and has a low rate of transient neurological symptoms (TNS), the prolonged sensory and motor block is a drawback for use in day-case spinal anesthesia. Similar to lidocaine, prilocaine is a local anesthetic with similar potency and duration of action and has been reported to have a lower incidence of TNS. Objective: To determine which local anesthetic, Prilocaine with added fentanyl versus bupivacaine with added fentanyl, is better in the setting of fast-track anesthesia in patients undergoing unilateral inguinal hernia. Material and methods: 70 Patients who were between 18-60 years old male patients, ASA grade I-II, BMI \< 35, undergoing elective unilateral inguinal hernia, standard surgical technique (open anterior prosthetic inguinal hernioplasty) inguinal hernia diagnosis is confirmed by ultrasonography, free medical history of micturition disorder, procedure lasting less than 90 minutes, having provided written informed consent signed by the patient or guardian were included. Those patients were divided into two groups. Group Pr (Prilocaine 40mg + fentanyl 25μ) and group Bu (Bupivacaine 7.5mg + fentanyl 25mcg)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Aug 2024

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 3, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2025

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

November 14, 2025

Completed
19 days until next milestone

First Posted

Study publicly available on registry

December 3, 2025

Completed
Last Updated

December 3, 2025

Status Verified

August 1, 2024

Enrollment Period

5 months

First QC Date

November 14, 2025

Last Update Submit

November 22, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • postoperative voiding

    time for the first spontaneous micturition

    first 2 hours postoperatively

Secondary Outcomes (1)

  • peak level of spinal anesthesia

    15 minutes

Study Arms (2)

prilocaine

ACTIVE COMPARATOR

Prilocaine 40mg (2ml) + fentanyl 25mcg in unilateral spinal anesthesia

Drug: Prilocaine

Bupivacaine

ACTIVE COMPARATOR

Bupivacaine 7.5mg (1.5ml) + fentanyl 25mcg in unilateral spinal anesthesia

Drug: Bupivacain

Interventions

Prilocaine 40mg (2ml) + fentanyl 25mcg in unilateral spinal anesthesia

prilocaine

Bupivacaine 7.5mg (1.5ml) + fentanyl 25mcg in unilateral spinal anesthesia

Bupivacaine

Eligibility Criteria

Age18 Years - 60 Years
Sexmale(Gender-based eligibility)
Gender Eligibility Detailsmales with no past history of urinary symptoms
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • ASA I-II.
  • BMI \< 35 kg/m2.
  • Absence of micturition disorder.
  • Patients scheduled for elective unilateral inguinal hernia with standard surgical technique (open anterior prosthetic inguinal hernioplasty) with previous ultrasonography confirmation of the diagnosis.

You may not qualify if:

  • Allergic to any drug being used in the study.
  • ASA III-IV.
  • Suffering from bulky inguinal/inguino-scrotal hernias.
  • Patients with infection at the injection site.
  • Non-cooperative patients.
  • Patients having sensory or motor deficit in lower extremities or history of micturition disorder, abnormal coagulation profile, history of alcohol or substance abuse.
  • contraindications or failure of spinal anesthesia and surgery lasting more than 90 minutes.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Theodor Bilharz Research institute

Giza, Egypt

Location

Related Publications (2)

  • Manish B. Kotwani, Kanchan Rupwate, Prashanth Shivananda, et al. Comparison between high dose hyperbaric Bupivacaine (12.5 mg) alone versus low dose hyperbaric Bupivacaine (7.5mg) with Fentanyl (25 μg) in spinal Anaesthesia for inguinal hernia surgery. Int J Clin Trials. 2016 Aug; 3(3):140-146.

    BACKGROUND
  • Rattenberry W, Hertling A, Erskine R. Spinal anaesthesia for ambulatory surgery. BJA Educ. 2019 Oct;19(10):321-328. doi: 10.1016/j.bjae.2019.06.001. Epub 2019 Aug 13. No abstract available.

    PMID: 33456853BACKGROUND

MeSH Terms

Interventions

PrilocaineBupivacaine

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Model Details: To compare unilateral intrathecal prilocaine versus bupivacaine with added fentanyl in both groups in inguinal hernia repair in the setting of fast-track anesthesia.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor of anesthesia

Study Record Dates

First Submitted

November 14, 2025

First Posted

December 3, 2025

Study Start

August 3, 2024

Primary Completion

December 30, 2024

Study Completion

January 15, 2025

Last Updated

December 3, 2025

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will share

data will be provided upon request from the principal investigator

Shared Documents
STUDY PROTOCOL
Time Frame
1/12/2025 till 30/12/2026
Access Criteria
researches

Locations